Can EGFR-TKIs be used in first line treatment for advanced non-small cell lung cancer based on selection according to clinical factors ? -- A literature-based meta-analysis

BACKGROUND: In the first line treatment of non-small cell lung cancer (NSCLC), several clinical trials have shown that not all NSCLC patients can benefit from treatment with tyrosine kinase inhibitors (TKIs) than receiving chemotherapy. Some trials treated patients with TKI according to their clinic...

Descripción completa

Detalles Bibliográficos
Autores principales: Xu, Chongrui, Zhou, Qing, Wu, Yi-long
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2012
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3507915/
https://www.ncbi.nlm.nih.gov/pubmed/23050865
http://dx.doi.org/10.1186/1756-8722-5-62

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3507915/
https://www.ncbi.nlm.nih.gov/pubmed/23050865
http://dx.doi.org/10.1186/1756-8722-5-62

Ejemplares similares